Zacks Investment Research downgraded shares of Sunshine Heart (NASDAQ:CHFS) from a buy rating to a hold rating in a research report report published on Thursday.

According to Zacks, “CHF Solutions, Inc. is a medical device company which focused on commercializing the Aquadex FlexFlow (R) System. Its commercial product Aquadex system, is indicated for temporary ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and extended ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. CHF Solutions Inc., formerly known as Sunshine Heart Inc., is headquartered in Minneapolis. “

Separately, ValuEngine cut shares of Sunshine Heart from a sell rating to a strong sell rating in a report on Monday, October 2nd.

Shares of Sunshine Heart (CHFS) traded up $0.31 during mid-day trading on Thursday, reaching $3.89. 2,883,772 shares of the company’s stock were exchanged, compared to its average volume of 766,425. Sunshine Heart has a twelve month low of $2.87 and a twelve month high of $137.00. The stock has a market capitalization of $6.44, a PE ratio of -0.02 and a beta of 2.25.

Sunshine Heart (NASDAQ:CHFS) last announced its earnings results on Tuesday, October 31st. The company reported ($4.55) EPS for the quarter. Sunshine Heart had a negative net margin of 263.73% and a negative return on equity of 165.61%. analysts predict that Sunshine Heart will post -3.03 EPS for the current year.

WARNING: This piece of content was reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this piece of content on another site, it was illegally copied and reposted in violation of US and international copyright & trademark law. The legal version of this piece of content can be read at https://theolympiareport.com/2018/01/20/sunshine-heart-chfs-rating-lowered-to-hold-at-zacks-investment-research.html.

About Sunshine Heart

CHF Solutions, Inc, an early-stage medical device company, develops cardiac and coronary disease products primarily in the United States. It focused on commercializing the Aquadex FlexFlow system, which is indicated for temporary ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization.

Get a free copy of the Zacks research report on Sunshine Heart (CHFS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Sunshine Heart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunshine Heart and related companies with MarketBeat.com's FREE daily email newsletter.